Seeking Alpha
 

Aetna, Inc. (AET)

- NYSE
  • Jul. 25, 2014, 11:05 AM
    • Led by the plummet in WellCare Health Plans (WCG -18.8%) the managed care industry can't seem to find a friend in the market today.
    • Related tickers: (UNH -1.3%) (WLP -1.9%) (AET -1.6%) (CI -1%) (HUM -2.8%) (CNC -6.6%) (HNT -2.3%) (MOH -5.4%) (MGLN -8.1%)
    | 2 Comments
  • Apr. 24, 2014, 9:28 AM
    | 1 Comment
  • Feb. 10, 2014, 2:19 PM
    • Arena Pharmaceuticals (ARNA +4.9%) and Japanese partner say their Belviq weight loss drug will be available to more people thanks to an agreement with pharmacy benefits manager CVS Caremark (CVS +0.6%), which means more than half of all Americans with insurance should now have access to the drug.
    • Aetna (AET) recently announced it would offer Belviq as a preferred brand to eligible patients as part of its pilot program to self-insured plan sponsors.
    • Belviq is approved for use in adults who are obese or who are overweight and have at least one serious medical condition, such as diabetes or high cholesterol.
    | Comment!
  • Oct. 28, 2013, 5:12 AM
    • The Affordable Care Act appears to have so far proved beneficial to investors in health insurers.
    • Over the past year, the share prices of the five top firms in the sector — Aetna (AET), WellPoint (WLP), UnitedHealth Group (UNH), Humana (HUM) and Cigna (CI) — have increased an average of 32%, well above the S&P 500's rise of 24%.
    • Health insurers predict that their earnings will rise after Obamacare is fully in effect, as they expect to gain more customers from people being forced to buy coverage. This is seen offsetting the cost of increased regulations. A fall in healthcare costs has also helped the sector.
    | Comment!
  • Oct. 17, 2013, 1:28 PM
    • Investors aren't satisfied with UnitedHealth's (UNH -4.9%) quarter, as the stock is notably lower on heavy volume.
    • Although the company matched Street estimates, profit ticked up only slightly Y/Y and the company's FY EPS guidance of $5.40-5.50 is still below consensus estimates.
    • Also lower on the day: WLP -1.4%, HUM -3.4%, AET -1.9%
    • Earnings
    | 1 Comment
  • Sep. 13, 2013, 9:03 AM
    • Aetna (AET) ticks 1.2% higher before the bell.
    • BofA upgrades the shares to Buy from Neutral.
    | Comment!
  • Apr. 1, 2013, 6:12 PM
    The Centers for Medicare and Medicaid Services, after originally calling for reducing Medicare Advantage payments in February, seem to have reversed course, now projecting that combined growth in Medicare Advantage rates and fee-for-service rates will be 3.3%. Though it's unclear precisely what that may mean for health insurers, the markets are taking it as a positive: HUM +9%, AET +2.3%, WCG +4.1%, UNH +4% AH.
    | 3 Comments
  • Apr. 1, 2013, 4:08 PM
    Health insurers surge into the close as the final notice on Medicare Advantage reimbursement is due today: Humana (HUM +8.6%), UnitedHealth (UNH +3.1%), Wellcare Healthplans (WCG +3.9%), Coventry Health (CVH +1%) Centene (CNC +1%) and Aetna (AET +2.5%).
    | Comment!
  • Feb. 19, 2013, 9:39 AM
    It's not just Humana (-9.6%) suffering from prospective declines in reimbursement rates for Medicare Advantage plans in 2014, with UnitedHealth (UNH) -5.2%, Cigna (CI) -5.5%, Aetna (AET) -3.5% and Universal America (UAM) -8.95%.
    | 7 Comments
  • Dec. 12, 2012, 10:06 AM
    Aetna (AET), which is holding its investor day, joins United Health and Cigna in providing 2013 guidance that's below consensus. Aetna forecasts EPS of at least $5.40 vs consensus of $5.52 and revenue growth of 9% to $38.6B vs $38.91B. Predicts that commercial-medical costs will rise 6.5%, the same as this year. BMO analyst Dave Shove says the outlook reflects "management’s cautious stance on guiding high." Shares +4.2%.
    | Comment!
  • Dec. 7, 2012, 9:34 AM
    Aetna (AET +2.4%) settles for $120M (subject to judge's approval) a class action suit relating to payments of claims to Aetna members who were served by non-contracted health-care providers. In other news, the stock is upgraded to Overweight with $52 price target by JPMorgan.
    | Comment!
  • Nov. 30, 2012, 12:30 PM
    More on Questcor (QCOR -6.4%): Aetna's (AET +0.3%) latest bulletin shows no change from its position first taken in September on Acthar. The insurer is still limiting reimbursement of the drug only for the treatment of infantile spasms. AET asserts that the drug's other approved uses are medically unnecessary or unproven.
    | 2 Comments
  • Nov. 21, 2012, 10:40 AM
    Weight loss drug makers get a lift today after Aetna (AET -0.6%) revises its criteria under which the insurer considers weight reduction medications as "medically necessary" for treatment of obesity. In a Clinical Policy Bulletin revision dated yesterday, AET identified certain medications that have been approved by the FDA for weight reduction which would be covered under its policy: Qsymia, marketed by VIVUS (VVUS +13.2%), Belviq from Arena Pharmaceuticals (ARNA +2.9%), Didrex from Pfizer (PFE +0.1%), Xenical from Roche (RHHBY +0.3) and GlaxoSmithKline's (GSK +0.2%) Alli. Orexigen (OREX +6.5%), although not named in the bulletin, is also higher on the news.
    | 11 Comments
  • Sep. 28, 2012, 3:43 PM
    Dendreon (DNDN +3.8%) bucks a weak tape today after Aetna (AET -0.4%) indicated on its website that it would pay for additional prostate cancer patients to be treated with Provenge, saying it now considers it to be medically necessary for treatment.
    | Comment!
  • Sep. 21, 2012, 2:38 PM
    Questcor Pharmaceuticals (QCOR +4.5%) continues to recover from Wednesday's dramatic drop of nearly 50%, as Roth Capital joins the chorus of analysts calling the reaction to the Aetna (AET) situation "overblown." QCOR's conference call yesterday "indicated that a highly-engaged and well-prepared reimbursement practice by QCOR has been successful and likely would continue as most cases are tightly sealed and more difficult for denial by insurers." the firm said in a note to clients.
    | Comment!
  • Sep. 20, 2012, 11:38 AM
    More on Questcor (QCOR +8.4%) conference call: COO Steve Cartt says insurance reimbursement for Acthar was already complicated before Aetna's (AET) coverage limitations, but QCOR is experienced in securing coverage for appropriate patients. "We anticipate that insurance coverage for Acthar will continue to be available" for the right patients."
    | Comment!
Visit Seeking Alpha's
AET vs. ETF Alternatives
Company Description
Aetna Inc. is a health care benefit company, which offers traditional and consumer-directed health insurance products and related services, including medical, pharmacy, dental, behavioral health, group life and disability plans.
Sector: Healthcare
Country: United States